Introduction {#s1}
============

AMPA-type glutamate receptors (AMPARs) are responsible for fast excitatory synaptic transmission in the brain. AMPAR channels are formed through the assembly of four AMPAR subunits. In excitatory neurons of the mature hippocampus, the majority of AMPARs consist of subunits GluA1 and GluA2 (GluA1/2 heteromers) or GluA2 and GluA3 (GluA2/3 heteromers) ([@bib71]). Each subunit has its individual properties based in part on the structure of the cytoplasmic C-terminal tail (C-tail). As an integral part of heteromeric AMPARs, the GluA2 subunit allows interactions with cytoplasmic proteins that control AMPAR transport to the cell surface and the endocytosis of AMPARs upon the induction of long-term depression of synapse strength (LTD) ([@bib5]). The GluA1 subunit has a unique C-tail that largely excludes GluA1-containing AMPARs from entry into synapses ([@bib61]). Upon the induction of long-term potentiation (LTP) or upon learning GluA1-containing AMPARs traffic into synapses, whereas a selective blockade of GluA1-trafficking prevent the expression of LTP and impairs memory formation ([@bib34]; [@bib50]; [@bib57]). In line with this, LTP and the formation of fear memories are severely impaired in GluA1-deficient mice ([@bib30]). The GluA1 C-tail contains several unique phosphorylation sites by which the trafficking of GluA1 to synapses can be regulated. For instance, the C-tail of GluA1 can be phosphorylated by protein kinase A (PKA) upon a rise in the levels of intracellular cyclic AMP (cAMP), which promotes GluA1-trafficking, lowers the threshold for LTP and facilitates the formation of memories ([@bib14]; [@bib16]; [@bib28]; [@bib51]). A recent study extended the AMPAR subunit-specific plasticity rules by showing that the N-terminal domain (NTD) of AMPAR subunits controls the anchoring of AMPARs at synapses, with a more stable anchoring of by the GluA2 NTD compared with the GluA1 NTD ([@bib70]).

Whereas the roles of GluA1 and GluA2 in hippocampal synaptic plasticity are well established, the significance of GluA3 has remained enigmatic. Although CA1 neurons express substantial amounts of GluA3 ([@bib35]), GluA3-containing AMPARs contribute little to synaptic and extra-synaptic AMPAR currents ([@bib43]; [@bib49]). In hippocampal neurons that lack GluA3 LTP and LTD are intact ([@bib49]; [@bib30]; [@bib54]) and the capacity of GluA3-deficient mice to acquire memories is comparable to wild-type congenics ([@bib1]; [@bib30]), inferring that GluA3-containing AMPARs do not play a prominent role in plasticity mechanisms that underlie memory formation. When recombinant GluA2/3s are expressed in CA1 neurons of hippocampal slices, they are continuously delivered to synapses independent of neuronal activity ([@bib61]). GluA2/3s that are expressed in neurons of the cortex become enriched at synapses when these neurons are deprived of experience-dependent input, implying a role for GluA2/3s in the homeostatic scaling of synaptic strength ([@bib46]). Interestingly, the presence of GluA3 is required for amyloid-β, the prime suspect to cause Alzheimer's disease, to mediate synaptic and memory deficits ([@bib54]).

In this study we show that GluA3-containing AMPARs are present at CA1 synapses in hippocampal slices, but transmit no or low currents upon glutamate binding under basal conditions. However, upon an increase in intracellular cAMP, for instance upon the activation of β-adrenergic receptors, GluA3-containing AMPARs become functional, leading to a novel type of synaptic potentiation.

Results {#s2}
=======

cAMP selectively increases currents through GluA3-containing AMPARs {#s2-1}
-------------------------------------------------------------------

To examine the contribution of GluA3 to the pool of extra-synaptic AMPARs, we recorded currents evoked by puffing AMPA onto outside-out membrane patches excised from cell bodies of CA1 pyramidal neurons in organotypic hippocampal slices prepared from wild-type, GluA3-deficient or GluA1-deficient mice ([Figure 1A,B](#fig1){ref-type="fig"}). Extra-synaptic AMPAR currents recorded from GluA3-deficient neurons were similar compared to those from with wild-type neurons (t-test, p\>0.9; [Figure 1A](#fig1){ref-type="fig"}). A non-stationary noise analysis on these outside-out AMPAR currents showed that the absence of GluA3-containing AMPAR currents did not result in differences in the average number of functional AMPARs per patch, single channel conductance or open-channel probability ([Figure 1C,D](#fig1){ref-type="fig"}). Consistent with previous results ([@bib4]), GluA1-deficient outside-out patches contained relatively few functional AMPAR channels, and those that were present had a low single-channel conductance and open channel probability ([Figure 1C,D](#fig1){ref-type="fig"}). As a result, currents were 83% smaller in the absence of GluA1 (t-test, p\<0.0001; [Figure 1A](#fig1){ref-type="fig"}), indicating that under basal conditions the majority of extra-synaptic AMPAR currents are derived from GluA1-containing AMPARs.

![cAMP increases currents of extrasynaptic GluA3-containing AMPARs.\
(**A**) Experimental setup, example traces and averages of AMPAR amplitudes in response to AMPA puffs onto outside-out patches from WT CA1 cell bodies without (black; n=15) or with (gray; n=24) cAMP in pipette, GluA3-KO without (dark blue; n=20) or with (light blue; n=20) cAMP, and GluA1-KO without (dark red; n=18) or with (light red; n=10) cAMP. Wild type and GluA1-deficient neurons showed an increased amplitude upon AMPA puffs in the presence of cAMP in the recording pipette, GluA3-deficient did not (t-test, WT: p=0.0009; t-test, 3KO: p=0.9; t-test, 1KO: p\<0.0001). All recordings in the presence of desensitization blockers cyclothiazide and PEPA and cAMP condition in the presence of PDE inhibitor IBMX. (**B**) Outside-out patches from SEP-GluA3 infected GluA3-KO cell bodies, before (n=7) and after (n=8) wash-in of forskolin plus IBMX. Sindbis expression of SEP-GluA3 in GluA3-KO neurons rescues GluA3-dependent plasticity (t-test, p=0.03). (**C**) Example graphs of non-stationary noise analysis for WT, GluA3-KO and GluA1-KO outside-out recordings. (**D**) Average number of functional channels, single channel conductance and open probability extracted from non-stationary noise analysis of the outside-out recordings from WT (ctrl: n=14; FSK/IBMX: n=16), GluA3-KO (ctrl: n=10; FSK/IBMX: n=11), or GluA1-KO (ctrl: n=8; FSK/IBMX: n=7) CA1 neurons (see methods). Upon forskolin and IBMX GluA1-deficient neurons show an increased number of functional channels (t-test, p=0.0009), single channel conductance (t-test, p=0.04) and open probability (t-test, p=0.002). (**E**) Example images and average fluorescence intensity of GluA3-KO cell bodies (left; n=10) and dendrites (right; n=12) infected with SEP-GluA3 visualized with 2-photon laser scanning microscopy before and after wash-in of forskolin plus IBMX shows no change in SEP levels (dendrite: t-test, p=0.4; cell bodies: t-test, p=0.﻿2). Scale bars indicate 5 μm. Error bars indicate SEM, \* indicates p\<0.05.](elife-25462-fig1){#fig1}

A rise in intracellular cAMP results in a potentiation of AMPAR currents ([@bib9]; [@bib11]; [@bib64]). To study how cAMP modifies AMPARs, we recorded AMPA-evoked currents from outside-out patches with or without cAMP in the solution of the recording pipette, while blocking cAMP degradation by phosphodiesterases (PDEs) with IBMX ([Figure 1A](#fig1){ref-type="fig"}). We note that IBMX by itself did not change the amplitude of the response to AMPA puffs ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In somatic membrane patches from wild-type neurons the amplitudes of the responses to AMPA puffs were 2-fold higher in the presence of cAMP ([Figure 1A](#fig1){ref-type="fig"}). In GluA3-deficient somatic patches cAMP failed to change AMPAR currents [Figure 1A](#fig1){ref-type="fig"}). In GluA1-deficient CA1 patches AMPAR currents increased 4.5-fold in the presence of cAMP ([Figure 1A](#fig1){ref-type="fig"}), which occurred as a function of an increase in the estimated number of functional channels, channel conductance and open-channel probability ([Figure 1C,D](#fig1){ref-type="fig"}). As a result, GluA3-containing AMPARs in GluA1-deficient patches activated by cAMP reached conductance levels comparable to those of GluA1-containing AMPARs in GluA3-deficient patches, the channel properties of which were not modified by cAMP ([Figure 1C,D](#fig1){ref-type="fig"}). These experiments suggest that cAMP selectively potentiated currents through extra-synaptic GluA3-containing AMPARs, revealing a novel type of AMPAR plasticity.

To examine whether GluA3-dependent plasticity involves trafficking of GluA3 to the cell surface, we introduced recombinant GluA3 into GluA3-deficient CA1 neurons using Sindbis virus. As a means to quantify the surface levels of recombinant GluA3, the subunit was tagged with super ecliptic phluorin (SEP), a GFP variant that is only fluorescent at neutral pH, i.e. when present in the ER, cis-Golgi or at the cell surface, but not at acidic pH in late endosomes or lysosomes. We visualized the pH-sensitivity of SEP-GluA3 by acutely washing in ACSF buffered at pH 5 ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Whereas SEP-GluA3 expression in GluA3-deficient neurons did not alter outside-out AMPAR currents, washing in both the adenylyl cyclase activator forskolin and PDE inhibitor IBMX rescued the cAMP-driven potentiation of AMPAR currents ([Figure 1B](#fig1){ref-type="fig"}), indicating that recombinant GluA3 responds similarly to a rise in cAMP as endogenous GluA3. However, the SEP fluorescence levels remained unchanged at the surface area of both dendrites and cell bodies upon the forskolin/IBMX wash-in ([Figure 1E](#fig1){ref-type="fig"}), suggesting that cAMP-driven GluA3-plasticity does not result from trafficking of GluA3-containing AMPARs from endocytic compartments to the cell surface.

cAMP increases the open-channel probability of GluA3 {#s2-2}
----------------------------------------------------

We examined whether cAMP-signaling can activate GluA2/3-channel function by performing single-channel recordings under cell-attached configuration from soma of CA1 pyramidal GluA1- or GluA3-deficient neurons from organotypic hippocampal slices, while adding AMPA to the recording pipette. AMPARs can have different conductance states depending on the number of AMPAR subunits that effectively bind glutamate ([@bib20]; [@bib55]). Three different open states could be distinguished in our single-channel AMPAR recordings ([Figure 2A,B](#fig2){ref-type="fig"}). Single-channel currents of AMPARs recorded from GluA3-deficient neurons did not change in the presence of forskolin ([Figure 2A](#fig2){ref-type="fig"}), indicating that the channel properties of GluA1-containing AMPARs remained unchanged upon a rise in cAMP. In contrast, GluA2/3s at the surface of GluA1-deficient neurons had a low open-channel probability under basal conditions and remained largely stuck in open state 1 ([Figure 2B](#fig2){ref-type="fig"}). In the presence of forskolin the open-channel probability was on average six-fold higher and GluA3-containing AMPARs more often reached open states 2 and 3. Their average conductance increased without modifying the conductance level per open state. These experiments indicate that GluA3-containing AMPARs are largely electrically quiet under basal conditions, but become functional upon a rise in cAMP by increasing their capacity for glutamate-gated channel opening.

![cAMP increases the open-channel probability of GluA3-containing AMPARs.\
(**A, B**) Single channel recordings under cell-attached configuration showing example traces, open probability, fraction of time spent in each open state, average conductance and conductances of each open state. (**A**) GluA1-containing AMPARs on GluA3-KO neurons (blue) did not respond to forskolin (ctrl: n=15, FSK: n=14) (open-channel probability: t-test, p=0.9; single-channel conductance: t-test, p=0.5). (**B**) The open-probability (t-test, p=0.0001) and single-channel conductance (t-test: p\<0.0001) increased of GluA3-containing AMPARs on GluA1-KO neurons (red) upon incubation with forskolin (ctrl: n=15, FSK n=14). Error bars indicate SEM, \* indicates p\<0.05.](elife-25462-fig2){#fig2}

A rise in cAMP activates GluA3-containing AMPARs at synapses {#s2-3}
------------------------------------------------------------

To investigate whether the cAMP-driven activation of GluA3-dependent plasticity occurs at synapses, we performed whole-cell patch clamp recordings on CA1 neurons from organotypic hippocampal slices in the presence or absence of forskolin. Forskolin incubation significantly increased AMPA/NMDA ratios evoked by stimulating Schaffer collateral inputs onto synapses of wild-type CA1 neurons ([Figure 3A](#fig3){ref-type="fig"}). Consistent with the notion that the potentiation effect of forskolin is predominantly postsynaptic ([@bib64]), forskolin did not affect presynaptic glutamate release, since paired pulse ratios did not change (ANOVA: WT: p=0.8, KO: p=0.9; [Figure 3B](#fig3){ref-type="fig"}) and the quantal content of evoked glutamate release determined by a variance analysis ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) did not increase. The variance analysis also revealed that AMPA/NMDA ratios increased as a function of increased AMPAR currents and not decreased NMDAR currents ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). At Sc-CA1 synapses of GluA3-deficient neurons however, forskolin did not change AMPA/NMDA ratios ([Figure 3A](#fig3){ref-type="fig"}), indicating that a rise in cAMP triggers potentiation of postsynaptic GluA3-containing AMPARs.

![The cAMP-driven postsynaptic potentiation depends on GluA3.\
(**A**) Example traces and average AMPA/NMDA EPSC ratios of WT neurons with (grey; n=13) or without (black; n=9) forskolin, and GluA3-KO neurons with (blue; n=8) or without (dark blue; n=8) forskolin. In WT neurons the AMPA/NMDA ratio increased upon forskolin incubation (ANOVA, p=0.02), but not in GluA3-KO neurons (ANOVA, p\>0.9). (**B**) Example traces and average paired pulsed ratio, which were not different in WT CA1 neurons with (n=8) or without (n=8) forskolin (ANOVA: p=0.9), or of GluA3-KO neurons with (n=8) or without (n=8) forskolin (ANOVA: p\>0.9). (**C**) In WT neurons mEPSC frequencies (t-test, p\<0.0001) and amplitudes (t-test, p=0.001) were higher in presence (n=16) versus absence (n=15) of forskolin. In GluA3-KO CA1 the mEPSC frequency (t-test, p=0.15) and amplitude (t-test, p=0.9) were not different in presence (n=9) or absence (n=8) of forskolin. In Sindbis-infected GluA3-KO neurons expressing GFP-GluA3 (blocked bars) the mEPSC frequency (t-test, p\<0.0001), but not amplitude (t-test, p=0.1), increased in presence (n=11) versus absence (n=8) of forskolin. The forskolin-driven fold increase in mEPSC frequency (ANOVA, p\<0.0001) and amplitude (ANOVA, p=0.006) was higher in WT versus GluA3-KO neurons. This fold increase in GFP-GluA3 infected versus uninfected GluA3-KO neurons was larger in mEPSC frequency (ANOVA, p=0.007), but not amplitude (ANOVA, p=0.4). (**D**) Forskolin increased mEPSC frequencies (t-test, p\<0.0001) and amplitudes (t-test, p=0.15) of GluA1-KO neurons (ctrl: dark red; n=11; FSK: light red; n=10), but not in GluA1/3-KO neurons (ctrl: dark purple; n=11; FSK: light purple; n=8). The forskolin-driven fold increase in mEPSC frequency (t-test, p\<0.0001) and amplitude (t-test, p=0.03) was larger in GluA1-KO versus GluA1/3-KO. (**E**) Non-stationary noise analysis of scaled mEPSCs revealed single-channel conductance of WT neurons with (n=10) or without (n=13) forskolin (t-test, p=0.009), GluA3-KO neurons with (n=8) or without (n=8) forskolin (t-test, p=0.9), and GFP-GluA3-expressing GluA3-KO neurons with (n=11) or without (n=8) forskolin (t-test, p=0.03), and forskolin-driven fold increase in single-channel conductance (WT vs GluA3-KO: ANOVA, p=0.07; GluA3-KO uninf. vs GFP-GluA3-inf: ANOVA, p=0.07). (**F**) Non-stationary noise analysis of scaled mEPSCs revealed single-channel conductance of GluA1-KO neurons with (n=8) or without (n=12) forskolin (t-test, p=0.01) and GluA1/3-KO neurons with (n=6) or without (n=11) forskolin (t-test, p=0.9), and forskolin-driven fold increase in single-channel conductance (t-test, p=0.02). (**G**) mEPSC distribution per 1 pA binned amplitude of GluA1-KO neurons without (dark red; n=11) or with (light red; n=10) forskolin and GluA1/3-KO neurons without (dark purple; n=11) or with (light purple; n=8) forskolin. (**H**) GluA3 exists as GluA2/3 heteromeric AMPARs. Example traces with corresponding I-V curve and average rectification indices ((I~-60mV~ -- I~0mV~) / (I~+40mV~ -- I~0mV~)) were determined in GluA1-KO organotypic slices of CA1 neurons without (n=6) or with (n=6) forskolin treatment (t-test, p=0.7). Error bars indicate SEM, \* indicates p\<0.05.](elife-25462-fig3){#fig3}

In miniature EPSC (mEPSC) recordings, the forskolin-driven postsynaptic potentiation was reflected as an increase in the frequency and amplitude of mEPSC events ([Figure 3C](#fig3){ref-type="fig"}). In GluA3-deficient neurons, forskolin did not significantly change the average mEPSC frequency or amplitude ([Figure 3C](#fig3){ref-type="fig"}). Re-introducing GluA3 in GluA3-deficient CA1 neurons by acute viral expression of GFP-GluA3 and allowing it to be expressed for 24 hr partially rescued the forskolin-driven synaptic potentiation ([Figure 3C](#fig3){ref-type="fig"}). GluA3-dependent synaptic potentiation was also induced by directly infusing cAMP into CA1 neurons with PDEs blocked by IBMX ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Neurons that are deficient in both GluA1 and GluA3 virtually lacked mEPSC events ([Figure 3D](#fig3){ref-type="fig"}), indicating that synaptic AMPAR currents recorded from GluA1-deficient CA1 neurons predominantly stem from GluA3-containing AMPARs. Whereas these GluA1/GluA3 double deficient neurons were insensitive to forskolin, forskolin did elevate the mEPSC frequency in GluA1-deficient neurons ([Figure 3B](#fig3){ref-type="fig"}). To determine whether the cAMP-driven synaptic potentiation could be explained by increased single-channel conductance, we conducted peak-scaled non-stationary fluctuation analyses from mEPSCs. The synaptic AMPAR single-channel conductance was significantly increased by forskolin only when cells express GluA3 ([Figure 3E,F](#fig3){ref-type="fig"}). These experiments indicate that postsynaptic currents of GluA3-containing AMPARs increase upon a rise in cAMP. A postsynaptic potentiation of GluA2/3 currents that is reflected by an increase in frequency rather than average amplitude may be explained by mEPSCs rising above the detection limit for mEPSC analysis. The distribution of mEPSC amplitudes recorded from GluA1-deficient CA1 neurons suggests that indeed a substantial proportion of mEPSC events fell below the 5 pA detection limit, and this proportion appeared smaller in the presence of forskolin ([Figure 3G](#fig3){ref-type="fig"}).

GluA3-containing AMPARs obligatorily exist as heteromers ([@bib13]), likely because structural constraints at their N-terminal domain prevent GluA3s from efficiently forming homomers ([@bib26]; [@bib68]). To test whether the forskolin-driven GluA3-dependent plasticity was mediated by GluA2/3 heteromers, we measured the AMPAR rectification indices in GluA1-deficient neurons. Unlike GluA2-containing AMPARs, GluA2-lacking AMPARs are rectifying: they conduct more easily at negative potentials. GluA1-deficient neurons displayed non-rectifying currents both in the absence and presence of forskolin ([Figure 3H](#fig3){ref-type="fig"}). Also when GFP-GluA3 was overexpressed in GluA3-deficient neurons, AMPAR currents remained non-rectifying in the presence of forskolin ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). These data indicate that GluA3-dependent plasticity at synapses predominantly stems from GluA2/3 heteromers.

Activation of GluA2/3s does not involve AMPAR trafficking {#s2-4}
---------------------------------------------------------

To examine whether cAMP-driven AMPAR-plasticity is accompanied with changes in AMPAR synaptic trafficking or lateral mobility, we performed time-lapse 2-photon imaging of CA1 neurons in wild-type organotypic slices infected with Sindbis virus to acutely express SEP-GluA3 or SEP-GluA1 together with cytoplasmic marker tdTomato. 24 hr after viral infection we assessed the fluorescence recovery after photobleaching (FRAP) of single spines ([Figure 4A](#fig4){ref-type="fig"}). The FRAP protocol did not affect the size of the photobleached spines nor the fluorescence signal in neighboring spines ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). After bleaching, the SEP-GluA3 and SEP-GluA1 fluorescence intensity recovered at a similar pace irrespective of forskolin/IBMX being present ([Figure 4B,C](#fig4){ref-type="fig"}). These data indicate that GluA3 and GluA1 show a similar lateral mobility at the surface of spines, which did not change upon a rise in cAMP.

![cAMP does not affect GluA2/3 mobility or trafficking to synapses.\
(**A**) Example image of a FRAP experiment: a spine from a CA1 neuron transfected with SEP-GluA3 + tdTomato obtained with two-photon microscopy immediately before, and 2, 5, 10, 20 and 30 min after photobleaching of the spine. (**B**) Left: Quantification of FRAP dynamics of spines transfected with SEP-GluA1 + tdTomato in the absence (dark blue; n=8) and the presence (light blue; n=6) of forskolin and IBMX. Right: Average fluorescence at time-points 20 min and 30 min after photobleaching of bleached spines (Ctrl: n=7, FSK/IBMX: n=8) in comparison to non-bleached neighboring spines (Ctrl: n=6, FSK/IBMX: n=6) in absence (ANOVA, p\>0.9) or presence (ANOVA, p=0.3) of forskolin (see [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). (**C**) Left: Quantification of FRAP dynamics of spines transfected with SEP-GluA3 + tdTomato in the absence (dark red; n=7) and the presence (light red; n=8) of forskolin and IBMX. Right: Average fluorescence at time-points 20 min and 30 min after photobleaching of bleached spines in comparison to unbleached neighboring spines (Ctrl: n=5, FSK/IBMX: n=5) in the absence (ANOVA, p=0.04) or presence (ANOVA, p=0.04) of forskolin (see [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Error bars indicate SEM, \* indicates p\<0.05.](elife-25462-fig4){#fig4}

Since AMPARs become immobilized when incorporated into synapses, the level of FRAP is indicative for the fraction of SEP-GluA3 or SEP-GluA1 located at synapses. As shown previously ([@bib45]), SEP-GluA1 fluorescence recovered to \~100% ([Figure 4B](#fig4){ref-type="fig"}), indicating that GluA1-containing AMPARs are largely excluded from entry into synapses under basal conditions. In the presence of forskolin/IBMX the recovery of SEP-GluA1 was lower (\~80%) although this did not reach significance ([Figure 4B](#fig4){ref-type="fig"}). SEP-GluA3 recovered to \~75% both in the absence and presence of forskolin/IBMX ([Figure 4C](#fig4){ref-type="fig"}), demonstrating that GluA2/3s are constitutively inserted into synapses independent of cAMP levels. These experiments are consistent with the model that synaptic GluA3-plasticity is expressed by an increase in channel conductance of GluA3-containing AMPARs already present at synapses.

A cAMP-driven activation of GluA2/3s requires PKA and Ras activity {#s2-5}
------------------------------------------------------------------

We next set out to identify the cAMP-dependent mediator that triggers GluA3-plasticity. A rise in cAMP can cause postsynaptic potentiation by triggering GluA1 phosphorylation via PKA activation ([@bib32]; [@bib47]). In line with this, adding the selective PKA activator N002 to the recording pipette significantly increased mEPSC frequency and amplitude in wild-type CA1 neurons ([Figure 5A](#fig5){ref-type="fig"}), and not in GluA1-deficient CA1 neurons ([Figure 5B](#fig5){ref-type="fig"}). Pre-incubation of wild-type CA1 neurons with PKA-inhibitors PKI ([Figure 5C](#fig5){ref-type="fig"}) or KT 5720 ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) failed to prevent the increase in mEPSC frequency. In GluA1-deficient CA1 neurons PKI also did not significantly block the forskolin-driven increase in mEPSC frequency ([Figure 5D](#fig5){ref-type="fig"}). These data indicate that PKA activation can trigger GluA1-dependent synaptic potentiation, but is not sufficient to promote GluA2/3-plasticity at synapses. We further excluded the involvement of the cAMP-dependent activation of HCN channels in GluA2/3-plasticity, since these channels were blocked by intracellular cesium during whole-cell recordings. We also found no evidence supporting a direct activation of GluA2/3 receptor complexes by cAMP: applying cAMP directly onto inside-out patches obtained from cell bodies of GluA1-deficient CA1 neurons did not change AMPAR conductance or open-channel probability ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

![PKA and Epac activation are not sufficient to activate GluA2/3-plasticity.\
(**A**) Example traces, mEPSC recordings of WT neurons with (n=12) or without (n=13) PKA agonist N002 in the recording pipette. N002 increased mEPSC frequency (t-test, p=0.004) and mEPSC amplitude (t-test, p=0.007). (**B**) Example traces, mEPSC recordings from GluA1-KO neurons with (n=13) or without (n=15) N002 in the recording pipette. N002 did not increase mEPSC frequency (t-test, p=0.06) and mEPSC amplitude (t-test, p=0.8) when GluA1 is not expressed. (**C**) Example traces, mEPSC frequencies and mEPSC amplitudes of untreated CA1 neurons (n=8), neurons incubated with forskolin (n=9), incubated with PKA inhibitor PKI (n=7), or preincubated with PKI prior to forskolin (n=10). PKI did not prevent the forskolin-driven increase in mEPSC frequency (ANOVA, ctrl vs FSK: p\<0.0001, PKI vs FSK/PKI: p\<0.0001). (**D**) Same as for (**B**) for GluA1-KO CA1 neurons either untreated (n=4), incubated with forskolin (n=5), incubated with PKI (n=5), or preincubated with PKI prior to forskolin (n=5) (ANOVA, ctrl vs FSK: p\<0.0001, PKI vs FSK/PKI: p=0.0001). (**E**) mEPSC recordings from wildtype CA1 neurons with control intracellular solution (n=7) or with Epac activator 8-CPT-2Me-cAMP in the recording pipette (n=7). 8-CPT-2Me-cAMP did not increase average mEPSC frequency (t-test, p=0.5) or amplitude (t-test, p=0.9) (**F**) WT CA1 neurons incubated with Epac inhibitor ESI-05 (n=12), forskolin (n=10) or preincubated with ESI-05 prior to forskolin (n=15). ESI-05 did not prevent the forskolin-driven synaptic potentiation (ANOVA, ESI-05 vs ESI-05/FSK: p\<0.0001; ESI-05 vs FSK: p\<0.0001; ESI-05/FSK vs FSK: p=0.4). Error bars indicate SEM, \* indicates p\<0.05.](elife-25462-fig5){#fig5}

A rise in cAMP can activate the small GTPases Rap1 and Ras ([@bib41]). Rap1 is activated by the Epac family of the cAMP-regulated guanidyl exchange factors (GEFs) ([@bib22]). Adding the Epac activator 8-CPT-2Me-cAMP (8CPT) to the recording pipette did not induce a change in mEPSC amplitude or frequency in CA1 neurons ([Figure 5E](#fig5){ref-type="fig"}), and a drug (ESI05) that inhibits Epac was unable to block the effect of forskolin ([Figure 5F](#fig5){ref-type="fig"}). In line with previous studies ([@bib21]; [@bib66]; [@bib73]), these data show that Epac/Rap1 signaling does not induce synaptic potentiation in CA1 neurons. Ras activation can be triggered by cAMP-dependent GEFs Ras-GRF1 and/or PDZ-GEF1 ([@bib3]; [@bib17]; [@bib41]) and leads to a synaptic potentiation in CA1 neurons ([@bib73]). For Ras signaling to occur at the cell membrane, a farnesyl group needs to be attached to the pre-Ras protein by farnesyltransferase (FT). The FT-inhibitor Salirasib partially blocked the forskolin-mediated increase in mEPSC frequency ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}), indicating that GluA2/3-plasticity involves a mediator that depends on FT activity. To directly test whether Ras mediates the cAMP-driven synaptic potentiation, CA1 neurons in acutely isolated brain slices were internally perfused with a Ras-specific IgG antibody, which binds the switch II region of H-, K-, and N-Ras, thereby inhibiting its conformational activation ([@bib8]), or with a control IgG. The infusion of anti-Ras or control IgG did not affect basal synaptic transmission in both wild-type and GluA1-deficient neurons ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Upon the wash-in of forskolin, the mEPSC frequency gradually increased irrespective of the anti-Ras or control IgG being present ([Figure 6A,B](#fig6){ref-type="fig"}, left), indicating that a blockade of Ras is not sufficient to prevent the cAMP-driven potentiation of GluA2/3 currents. A previous study showed that in neurons the cAMP-driven activation of Ras is in part dependent on PKA ([@bib3]). To test whether PKA and Ras cooperate to mediate cAMP-driven synaptic potentiation, we repeated this experiment in the presence PKA-inhibitor PKI ([Figure 6A,B](#fig6){ref-type="fig"}, right and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). When both PKA and Ras were blocked in wild-type CA1 neurons, the mEPSC frequency did not increase upon forskolin wash-in, although the forskolin-mediated fold increase in mEPSC frequency was not significantly different between Ras and ctrl IgG ([Figure 6A](#fig6){ref-type="fig"}). In GluA1-deficient neurons, in which the GluA2/3 currents are isolated, the blockade of both Ras and PKA did fully prevent the forskolin-driven fold increase in mEPSC frequency ([Figure 6B](#fig6){ref-type="fig"}). These experiments indicate that the cAMP-driven signaling pathway that triggers activation of GluA2/3-plasticity requires the activation of both PKA and Ras.

![cAMP activates GluA2/3-plasticity through a PKA- and Ras-dependent signaling pathway.\
(**A--B**) Miniature EPSC recordings with anti-Ras IgG or control IgG in recording pipette from CA1 neurons in brain slices acutely isolated from mature wild type and GluA1-KO mice. After ten minutes baseline recording to allow antibody to perfuse into the cell, forskolin and IBMX were washed in the extracellular solution. (**A**) Upon the wash-in of forskolin, WT neurons showed an increase in mEPSC frequency in the presence of control IgG (paired t-test, p\<0.001) and anti-Ras IgG (paired t-test, p\<0.001), but not in mEPSC amplitude (paired t-test, ctrl-IgG: p=0.7; RAS-IgG: p=0.055). Stars indicate a significant increase at 15--20 min compared to the 10 min baseline. In the presence of PKI, the wash-in of forskolin led to a significant increase in frequency in neurons perfused with control IgG (paired t-test, p=0.007), but not with Ras IgG (paired t-test: p=0.07). Comparisons between the fold changes did not yield significant results (ANOVA, p=0.12; IgG: n=7; Ras: n=9; IgG/PKI: n=10; Ras/PKI: n=9). (**B**) In GluA1-deficient neurons, the wash in of forskolin also increased mEPSC frequency regardless of the antibody (paired t-test, ctrl-IgG: p\<0.001; Ras-IgG: p\<0.0001). mEPSC amplitudes were not affected by forskolin (paired t-test, ctrl-IgG: p=0.7; Ras-IgG: p=0.3). In the presence of PKI neurons perfused with control IgG show a significant increase in frequency upon the wash in of forskolin (paired t-test, p=0.006). In neurons with Ras-IgG this potentiation was absent (paired t-test: p=0.15). The fold increase in mEPSC frequency is blocked by the anti-Ras antibody in the presence of PKI in GluA1-KO neurons (ANOVA, IgG/PKI vs Ras/PKI: p=0.03; IgG vs Ras/PKI: p=0.04; IgG: n=11; Ras-IgG: n=12; IgG/PKI: n=10; Ras-IgG/PKI: n=14). Error bars indicate SEM.](elife-25462-fig6){#fig6}

β-adrenergic signaling triggers the activation of GluA2/3-plasticity {#s2-6}
--------------------------------------------------------------------

A rise in intracellular cAMP in neurons can be achieved upon the release of norepinephrine (NE) through the activation of β-adrenergic receptors (β-ARs) ([@bib60]) and β-ARs activation by selective agonist isoproterenol induces both PKA and Ras signaling ([@bib15]). Isoproterenol by itself is known to generate only a weak increase in intracellular cAMP and inefficiently triggers downstream signaling due to a negative feedback loop activating PDEs ([@bib12]; [@bib7]; [@bib27]). To assess whether isoproterenol can induce GluA2/3-plasticity, we performed a mEPSC analysis on CA1 excitatory neurons of the dorsal hippocampus in brain slices acutely isolated from mature mice. When these slices were incubated with isoproterenol we observed an increased frequency, but not amplitude, of mEPSC events in CA1 neurons of both wild-type and GluA1-deficient mice, provided that PDE activity was inhibited with IBMX ([Figure 7](#fig7){ref-type="fig"}). Isoproterenol did not trigger synaptic potentiation in CA1 neurons of GluA3-deficient brain slices ([Figure 7](#fig7){ref-type="fig"}), indicating that β-AR activation can evoke GluA3-dependent plasticity upon a robust increase in cAMP levels.

![β--adrenergic activation induces GluA2/3--plasticity.\
Brain slices were acutely isolated from mature WT and littermate GluA3-KO mice, or GluA1-KO mice. Example traces, average mEPSC frequencies and amplitudes from CA1 neurons incubated with no drugs, b-AR agonist isoproterenol, PDE blocker IBMX, or isoproterenol plus IBMX (WT: ctrl n=13, Iso n=11, IBMX n=7, Iso + IBMX n=9; GluA3-KO: ctrl n=15, Iso n=7, IBMX n=7, Iso+IBMX n=4; GluA1-KO: ctrl n=5, Iso n=4, IBMX n=8, Iso+IBMX n=6). Isoproterenol in presence of IBMX increases mEPSC frequency in WT (ANOVA, ctrl vs Isopr: p=0.8; IBMX vs Isopr/IBMX: p\<0.0001), and GluA1-KO (ANOVA, ctrl vs Isopr: p=0.4; IBMX vs Isopr/IBMX: p=0.001), but not in GluA3-KO (ANOVA, ctrl vs Isopr: p=0.9; IBMX vs Isopr/IBMX: p=0.5). Isoproterenol/IBMX did not affect average mEPSC amplitude in WT (ANOVA, p=0.4), in GluA3-KO (ANOVA, p=0.4), or in GluA1-KO neurons (ANOVA, Isopr vs isopr/IBMX p=0.045). Error bars indicate SEM, \* indicates p\<0.05.](elife-25462-fig7){#fig7}

To examine whether GluA3-dependent plasticity can be induced in vivo through NE release, epinephrine (E) or saline as a control was injected intraperitoneally in mature mice. E stimulates the locus coeruleus (LC) to supply NE throughout the nervous system, which enhances arousal and reduces the exploratory locomotor activity in rodents ([@bib10]; [@bib42]). When mice were placed in a novel environment 10 min after E-injection, wild-type, GluA3-deficient and GluA1-deficient mice showed decreased locomotion ([Figure 8A](#fig8){ref-type="fig"}), suggesting that LC-activity is intact in GluA3- and GluA1-deficient mice. In brain slices prepared 10 min after E-injection we observed a significant increase in mEPSC frequency in CA1 neurons of wild-type and GluA1-deficient mice compared with saline-injected littermates ([Figure 8B](#fig8){ref-type="fig"}). No increase in mEPSC frequency was detected when GluA1-deficient mice were injected with β-AR antagonist propranolol 20 min prior to E-injection ([Figure 8B](#fig8){ref-type="fig"}), indicating that potentiation of GluA2/3-currents depended on β-AR activation. In slices isolated from E-injected GluA3-deficient mice we failed to detect an increase in mEPSC events ([Figure 8B](#fig8){ref-type="fig"}). To assess whether synaptic potentiation upon E-injection required GluA3 in CA1 neurons, we repeated this experiment in mice that lacked GluA3 expression selectively in a subset of CA1 neurons. Three-week-old mice, whose GluA3 gene was flanked by loxP sites, (flGluA3) were stereotactically injected with AAV virus expressing either GFP-tagged Cre-recombinase (Cre-GFP) or GFP under control of the Synapsin1 promoter in the CA1 region of the hippocampus. After allowing Cre-GFP to delete the GluA3 gene and deplete GluA3 expression for three weeks, we injected E or saline intraperitoneally and measured mEPSCs on GFP-positive CA1 neurons from slices prepared 10 min after injection. Whereas the synaptic effect of E-injection was evident in slices prepared from mice injected with control GFP-virus, it was significantly reduced in neurons where GluA3 expression had been stopped out by Cre-GFP ([Figure 8C](#fig8){ref-type="fig"}). These data indicate that NE-release induces potentiation of GluA2/3-currents at CA1 pyramidal synapses in the hippocampus.

![NE release triggers the activation of GluA2/3-plasticity.\
(**A**) Example traces and average motion as a change in significant motion pixels (SMPs) (Kopec et al., 2007) of WT injected with saline (n=15) or E (n=15), GluA3-KO injected with saline (n=17) or E (n=16), and GluA1-KO injected with saline (n=10) or E (n=11). Epinephrine (E) injection decreases the motion of mice (t-test, WT: p=0.003; GluA3-KO: p=0.02; GluA1-KO: p=0.01). (**B**) Example traces, mEPSC frequencies and mEPSC amplitudes of CA1 hippocampal neurons from WT mice injected with saline (n=13) or E (n=15) (t-test, Freq: p=0.0003; Ampl: p=0.6); GluA3-KO mice injected with saline (n=16) or E (n=13) (t-test, Freq: p=0.4; Ampl: p=0.5); or GluA1-KO mice injected with saline (n=12), E (n=20) or propranolol 20 min prior to E (n=16) (Freq: ANOVA, veh vs E: p=0.008; E vs E + Prop: p=0.04; veh vs E + Prop: p\>0.9) (Ampl: ANOVA, p=0.2). (**C**) AAV virus expressing GFP or GFP-Cre were stereotactically targeted at the CA1 of flGluA3 mice. Example traces, mEPSC frequencies and mEPSC amplitudes recorded from GFP-positive CA1 neurons after injection with epinephrine (GFP: n=11; GFP-Cre: n=9) or saline (GFP: n=11; GFP-Cre: n=11). In GFP-infected neurons E-injection caused an increased mEPSC frequency (t-test, p\<0.0001) and decreased amplitude (t-test, p=0.02). In GFP-Cre infected neurons E-injection caused a decrease in mEPSC frequency (t-test, p=0.02) and no change in amplitude (t-test, p=0.6). Error bars indicate SEM, \* indicates p\<0.05.](elife-25462-fig8){#fig8}

Discussion {#s3}
==========

In this study we identified a novel form of synaptic plasticity in the CA1 region of the hippocampus that depends on GluA3-containing AMPARs. Historically, AMPARs of hippocampal neurons have been assumed to predominantly consist of GluA1/2s with only a small proportion of GluA2/3s. This notion was based on the observations that mRNA levels of GluA3 are 10-fold lower compared with GluA1 and GluA2 mRNA levels ([@bib69]) and that GluA2/3s contribute little to synaptic and extrasynaptic AMPAR currents ([@bib4]; [@bib43]). However, the total protein levels of GluA3 in the hippocampus were shown to be substantial ([@bib59]), and it was estimated that the AMPAR population in CA1 dendrites is composed of equivalent amounts of GluA1/2s and GluA2/3s ([@bib35]). We here unify these seemingly contradictory findings by showing that GluA3-containing AMPARs are present at synapses and on the cell surface; however, they are electrically quiet under basal conditions.

GluA3-mediated currents substantially increase when intracellular cAMP levels are increased in CA1 neurons. Our single-channel recordings indicate that these increased currents are a consequence of an improved capacity of glutamate to open the AMPAR channel. GluA1-containing AMPARs opened their channels independently of cAMP levels, suggesting that this type of AMPAR channel plasticity is an exclusive feature of GluA2/3s. The activation of GluA2/3-plasticity by cAMP is fast, since outside-out patches were pulled from whole-cell configuration after allowing cAMP to flow inside the cell for less than \~10 s. Our experiments indicate that PKA activation is insufficient for the cAMP-driven activation of GluA2/3-plasticity but requires the activation of both PKA and Ras. A cAMP-dependent signaling pathway that depends on both PKA and Ras activation is the extracellular signal-regulated kinase (Erk) ([@bib40]; [@bib15]; [@bib3]). However, whether PKA either promotes Ras-Erk signaling or inhibits Erk (thereby possibly skewing Ras activation towards an alternative Ras-signaling pathway) is dependent on the levels of additional signaling factors and on cell type ([@bib63]; [@bib52]). Which downstream targets of PKA/Ras activate GluA2/3-plasticity in CA1 neurons and how they alter GluA2/3-channel function remains to be established. Future structural studies may reveal whether PKA/Ras signaling triggers a putative conformational change within the GluA3 subunit that allows either glutamate to access the ligand binding site or glutamate binding to open the channel.

The cAMP-driven activation of GluA2/3s at the surface of cell bodies mirrors GluA2/3-plasticity at synapses: both increased approximately two-fold in currents upon a rise in cAMP. These results imply that similar to its total levels at CA1 dendrites ([@bib35]) approximately half of the synaptic and extrasynaptic AMPAR population consists of GluA2/3s. When recombinant GluA3 was acutely expressed in GluA3-deficient CA1 neurons of organotypic slices, the newly formed GluA3-containing AMPARs were inserted onto to the surface and into synapses without a change in synaptic or extrasynaptic AMPAR currents. However, upon a rise in cAMP they showed increased currents at both synaptic and extrasynaptic sites without a change in GluA3 levels at synapses or at the cell surface. Our results therefore indicate that GluA3-containing AMPARs constitutively traffic into synapses in an inactive state and only contribute to synaptic currents after cAMP levels have risen. In contrast, GluA1-containing AMPARs are largely kept out of the synapse under basal conditions and require LTP-like activity to traffic into synapses ([@bib35]; [@bib45]; [@bib61]). A recent study showed that LTP can be expressed by the insertion of both GluA1-containing and GluA1-lacking AMPARs into synapses ([@bib23]). Although this study did not show whether this is also the case for GluA2/3s, our finding that GluA2/3s are electrically dormant under basal conditions may explain why LTP is not visible in GluA1-deficient hippocampal slices ([@bib23]; [@bib30]; [@bib72]). A previous study showed that a slowly arising LTP can be seen in GluA1-deficient slices when a theta-burst stimulation is paired with a postsynaptic depolarization ([@bib18]). We speculate that upon this stimulation protocol a gradual increase in cAMP levels may have activated GluA2/3-plasticity.

In our experiments a postsynaptic change in AMPAR currents was reflected more prominently by a change in mEPSC frequency than by a change in mEPSC amplitude, which has been observed previously ([@bib70]; [@bib39]; [@bib43]; [@bib56]) and is a consequence of a large proportion of mEPSCs recorded from CA1 neurons falling below the 5 pA detection limit ([Figure 3G](#fig3){ref-type="fig"}). An increase in mEPSC frequency rather than mEPSC amplitude upon the activation of GluA2/3-plasticity may be further explained by the findings that GluA1/2s and GluA2/3s are differentially distributed at CA1 synapses. Whereas GluA3 is uniformly distributed within synapses, GluA1 tends to be more concentrated towards their edges ([@bib31]) and large CA1 synapses are particularly enriched in GluA1 ([@bib62]). When a mEPSC is generated by the release of a single vesicle onto a micro-domain within a synapse ([@bib44]) that predominantly contains GluA2/3s, its amplitude may only surpass the detection limit after a rise in cAMP. Reversely, glutamate binding to a micro-domain that contains mainly GluA1 and little GluA3 may produce mEPSCs that are detectable under basal conditions, but the amplitude of such mEPSCs will benefit only little from GluA2/3-plasticity. In such a scenario, the frequency of mEPSC events increases more than their average amplitude. Similarly, CA1 neurons, in which either GluA1 or GluA3 are depleted, are mostly affected in mEPSC frequency and little in amplitude ([@bib43]). We therefore propose that variations in mEPSC frequency, if not caused by a change in presynaptic vesicle release or the number of functional synapses, can be a manifestation of a postsynaptic AMPAR subunit-specific effect.

Besides the hippocampus, GluA3-containing AMPARs are present in most other brain regions, including the cortex, amygdala, striatum, thalamus, brain stem, olfactory bulb, nucleus accumbens and cerebellum ([@bib6]; [@bib53]; [@bib59]), suggesting that GluA2/3-plasticity may be operative throughout the brain. GluA3-deficient mice show a number of physiological and behavioral abnormalities, which may putatively depend on GluA2/3-plasticity in different brain regions. For instance, GluA3-deficient mice show increased social and aggressive behavior ([@bib1]), a reduced alcohol-seeking behavior ([@bib58]), impaired auditory processing ([@bib19]), and altered electroencephalographic patterns in the cortex during sleep ([@bib65]). Based on the findings in this study, we examined the role of GluA3-dependent plasticity at synapses onto Purkinje cells (PCs) of the cerebellum ([@bib24]). We found that the AMPAR-subunit specific rules for synaptic plasticity in PCs were reversed compared with CA1 neurons: motor learning and the expression of LTP did not require GluA1, but critically depended on GluA3. Similarly as at CA1 synapses, synaptic potentiation was accomplished by the activation of GluA3-channel function upon a rise in cAMP. An interesting difference is that GluA3-dependent plasticity in PCs is mediated by Epac/Rap1 ([@bib24]). Since Ras and Rap1 trigger similar downstream (Erk) signaling pathways with different temporal patterns ([@bib41]), Ras and Rap1 may activate a transient or persistent form of GluA2/3-plasticity respectively. Thus, GluA2/3-plasticity may have different functions contingent on the cell type and brain regions in which it is expressed.

The activation of β-ARs at CA1 neurons of the hippocampus can stimulate two independent forms of AMPAR plasticity in parallel. First, PKA phosphorylation of GluA1-containing AMPARs facilitates their trafficking to synapses ([@bib47]), thereby facilitating memory formation ([@bib28]). We identified a second cAMP-dependent form of AMPAR plasticity. Our data show that GluA2/3s at synapses increase their currents upon β-AR activation. Other signaling pathways that influence intracellular cAMP levels, like for instance those activated by dopamine, serotonin or acetylcholine release, may theoretically influence GluA3-containing AMPARs as well. It will be interesting to assess under which conditions GluA3-containing AMPARs in the hippocampus are activated and how GluA2/3-plasticity influences the formation and retrieval of contextual memories.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

The *Gria3*-deficient (GluA3-KO) and wild-type littermate colony was established from C57Bl/6 × 129P2-Gria3tm1Dgen/Mmnc mutant ancestors (RRID:[MMRRC_030969-UNC](https://scicrunch.org/resolver/MMRRC_030969-UNC)) (MMRRC, Davis, CA), which were at least 6 times backcrossed to C57Bl/6 mice. *Gria1*-deficient (GluA1-KO) mice were a kind gift from Dr. R. Huganir ([@bib37]), and a colony was generated by mating heterozygous C57Bl/6/129 mice. *Gria1xGria3* double deficient colony was established by crossing homozygote *Gria1*-deficient males with heterozygote *Gria3*-deficient females. Mice with floxed loci at the *Gria3* gene \[*Gria3^lox/lox^* (RRID:[IMSR_EM:09215](https://scicrunch.org/resolver/IMSR_EM:09215))\] were a kind gift from Dr. R. Sprengel ([@bib58]) and maintained in a homozygous colony. Mice were kept on a 12 hr day-night cycle (light onset 7am) and had *ad libitum* access to food and water. All experiments were conducted in line with the European guidelines for the care and use of laboratory animals (Council Directive 86/6009/EEC). The experimental protocol was approved by the Animal Experiment Committee of the Royal Netherlands Academy of Arts and Sciences (KNAW).

Electrophysiology {#s4-2}
-----------------

Organotypic hippocampal slices were prepared from P7-8 mice as described previously ([@bib67]) and used at 7--12 days in vitro. Where indicated, slices were infected with Sindbis virus expressing GFP- or SEP-tagged rat GluA3 (flip) 20--28 hr prior to experiments. During recordings, slices were perfused with artificial cerebrospinal fluid (ACSF; in mM): 118 NaCl, 2.5 KCl, 26 NaHCO~3~, 1 NaH~2~PO~4~, supplemented with 4 MgCl~2~, 4 CaCl~2~, 20 glucose. Patch recording pipettes were filled with internal solution containing (in mM): 115 CsMeSO~3~, 20 CsCl, 10 HEPES, 2.5 MgCl~2~, 4 Na~2-~ATP, 0.4 Na-GTP, 10 Na-Phosphocreatine, 0.6 EGTA. Outside-out recordings were made with 3--5 MΩ pipettes and the bath contained the desensitization blockers PEPA (80 µM; Tocris) and cyclothiazide (100 µM; Tocris) to exclude variations due to differences in desensitization properties. Every 20 s a 100 ms puff of 100 μM S-AMPA was delivered with a Picospritzer III (Parker, Hollis, USA). Single channel recordings were measured under cell-attached configuration with 6--8 MΩ pipettes filled with internal solution to which S-AMPA (100 μM; Tocris) was added. Whole-cell recordings in organotypic slice cultures were made with 3--5 MΩ pipettes (R~access~ \< 20 MΩ, and R~input~ \> 10× R~access~). During mEPSC recordings, TTX (1 μM; Tocris) and picrotoxin (100 μM; Sigma) were added to the bath. Where indicated, the following drugs were added to the perfusion solution: forskolin (50 μM; Sigma), IBMX (50 μM; Tocris), KT5720 (4 μM; Tocris), PKI (2 μM; Calbiochem), ESI05 (10 μM; Biolog); Salirasib (10 μM; Tocris); or inside the recording pipette: cAMP (100 μM; Sigma), N002 (100 μM; Biolog), 8-CPT (20 μM; Tocris). During evoked recordings, a cut was made between CA1 and CA3, and picrotoxin (50 μM) and 2-chloroadenosine (4 μM; Tocris) were added to the bath. Two stimulating electrodes, (two-contact Pt/Ir cluster electrode, Frederick Haer), were placed 100 μm apart between 100 and 300 μm down the apical dendrite and 200 μm apart laterally. AMPAR-mediated EPSCs were measured as the peak inward current at −60 mV directly after stimulation. Paired pulse ratios were determined with an inter pulse interval of 50 ms. NMDAR-mediated EPSC were measured as the mean outward current between 40 and 90 ms after the stimulation at +40 mV, and corrected by the current at 0 mV. Rectification was calculated as the ratio of the peak AMPAR current at −60 and +40 mV, corrected by the current at 0 mV, in the presence of D-APV (100 μM; Tocris) in the bath and Spermine (0.1 mM; Sigma) in the intracellular solution. EPSC amplitudes were obtained from an average of at least 30 sweeps at each holding potential. Acute hippocampal slices were prepared from 3 to 5 week-old mice. Dissection was done in ice-cold sucrose cutting solution containing (in mM): 2.5 KCl, 1.25 NaH~2~PO~4~, 26 NaHCO~3~, 10 D-glucose, 230 Sucrose, 0.5 CaCl~2~, 10 MgSO~4~, bubbled with 95%O~2~/5%CO~2~. Brain slices (400 μm) were cut using a vibratome (Thermo Scientific) and placed in a holding chamber containing ACSF supplemented with (in mM) 1 MgCl~2~, 2 CaCl~2~, 20 glucose and bubbled with 95%O~2~/5%CO~2~. They were allowed to recover at 34°C for 40 min then at room temperature for at least 40 min. Whole-cell recordings (3--5 MΩ pipettes, R~access~ \< 26 MΩ, and R~input~ \> 10 x R~access~) were made in ACSF containing TTX (1 μM) and picrotoxin (50 μM) at 28°C. To block Ras, 3 μg/ml the OP01 Anti-v-H-Ras (Ab-1) Rat mAb (Y13-259, Millipore; RRID:[AB_565094](https://scicrunch.org/resolver/AB_565094)) or Rat IgG1 isotype control (MA1-90035, Invitrogen; RRID:[AB_10984952](https://scicrunch.org/resolver/AB_10984952)) was included in the intracellular solution. After obtaining whole-cell configuration the antibody was allowed to diffuse in the cell for 5 min before recording. After 10 min FSK was added to the perfusion and allowed to wash in for 5 min. Data was acquired using a Multiclamp 700B amplifier (Molecular Devices). mEPSC data are based on at least 100 events or 5 min of recording, with exception of [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} (1 min). Data were analyzed with MiniAnalysis (Synaptosoft). Individual events above a 5 pA threshold were manually selected. Evoked recordings were analyzed using pClamp 10 software (Molecular Devices).

Non-stationary noise analysis of outside-out patches traces was carried out following previously described methods ([@bib2]; [@bib25]). Peak aligned AMPA-evoked currents recorded over 10--15 sweeps per outside out patch, were binned in 10 equally sized bins of 150 ms each and for each bin, the mean amplitude and variance was calculated. The data distribution resulting after plotting amplitude versus variance was fitted with the following equation: $\sigma^{2} = iI - \frac{I^{2}}{N} + \sigma_{b}^{2}$, where the variance (σ^2^) of the amplitude of the current (I) obtained at each time point is explained as a function of the single unitary current (i) and the number of functionally conducting channels (N) with an offset given by the variance of the baseline noise (σ^2^~b~). From the derivative at I=0, the relative number of functional channels was extracted as well as the single channel conductance which was calculated by dividing the unitary current by the applied voltage with respect to the reversal potential (V~holding~-E~reversal~, −60 mV and 0 mV respectively). The peak open probability (P~o~), corresponding to the fraction of available functional channels open at the time of the peak current (I~peak~), can be calculated from the following equation: $P_{0} = I_{peak}/N_{max}$, where N~max~ represents the theoretical maximum of available channels opened at the point where the theoretical maximum amplitude reaches the minimum variability (σ^2^~b~) in the given parabola fit. Single channel activity was analyzed using ClampFit (Molecular Devices). Three detection thresholds were used to detect O1 (1.5 pA), O2 (3 pA) and O3 (4.5 pA) openings in single channel AMPARs in steady baseline recordings (no holding current fluctuations). Events with latency shorter than 0.3 ms were ignored to prevent noise from being recognized as openings. Non-stationary noise analyses for the mEPSC events were based on peak scaled mEPSCs.

Two-photon laser scanning microscopy {#s4-3}
------------------------------------

Wild-type organotypic hippocampal slices were sparsely infected with Sindbis virus expressing SEP-GluA1 or SEP-GluA3 together with tdTomato as cytoplasmic marker, and were used in experiments 20--28 hr after viral infection. Three-dimensional images were collected on a custom-built two-photon microscope based on a Fluoview laser-scanning microscope (Femtonics). The light source was a mode-locked Ti:sapphire laser (Chameleon, Coherent) tuned at 910 nm using a 20× objective. During imaging, slices were kept under constant perfusion of aCSF (in mM: 118 NaCl, 2.5 KCl, 26 NaHCO~3~, 1 NaH~2~PO~4~, supplemented with 4 MgCl~2~, 4 CaCl~2~, 20 glucose) at 30°C, gassed with 95%O~2~/5%CO~2~. Images were captured every 1 μm from infected CA1 pyramidal cell bodies or apical dendrites past the point of bifurcation of primary to secondary dendrites, approximately 300 μm from the cell body. Fluorescence intensity was quantified from projections of stacked sections using ImageJ software (NIH). For photobleaching experiments, apical dendrites were imaged 100--300 μm from the cell body (pixel size x,y,z 0.1 × 0.1 × 0.5 μm). Photobleaching of SEP-fluorescence on spines was achieved by prolonged xy scanning for 30 s. The cytoplasmic tdTomato signal recovered immediately after photobleaching ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). To determine the photon recovery after photobleaching (FRAP), background-subtracted and leak-corrected red and green fluorescence were quantified and the mean signal intensity of spines was normalized to that of the dendrite and compared across time.

Stereotactic hippocampal viral injections and E-injection {#s4-4}
---------------------------------------------------------

Adeno-associated virus (AAV) with a titer between 10^12^--10^13^ particles/ml were produced from AAV5-pSynapsin1-GFP and AAV5-pSynapsin1-CreGFP. 3 week-old *Gria3^lox/lox^* mice were anesthetized with isofluorane (induction 5%, maintenance 2%) and positioned in a stereotaxic apparatus, kept on a heating pad. Bilateral hippocampal injections of viral solutions (3 injection sites per side; 400 nl per site; AP: −1.5, --1.7, −1.9; L: ±1.5; DV: 1.2 mm) were delivered with a glass micropipette through a hole drilled in the skull by pressure application (Nanoject II, Auto-Nanoliter Injector, Drummond Scientific). E-injection experiments were performed with *Gria3^lox/lox^* mice 3 weeks after viral injections, or with WT, GluA3-KO or GluA1-KO littermate mice at 3--4 weeks of age. (±)-Epinephrine hydrochloride (0.5 mg/kg, Sigma-Aldrich) and (±)-Propranolol hydrochloride (20 mg/kg, Sigma-Aldrich) were dissolved in saline (0.9%, NaCl) and injected intraperitoneally (5 ml/kg). 10 min after E-injection mice were place in a novel environment for 2 min and the locomotion of the mice was measured as previously described ([@bib38]) or they were sacrificed to acutely isolate brain slices.

Statistics {#s4-5}
----------

A power analysis was performed prior the experiments to estimate the average sample size. For power analyses 2-sample, two-sided tests were used with the assumption of equal variance, a power of 0.8 and a Type I error (alpha) of 0.05 were used. If effect sizes could not be estimated based on prior experiments a minimal effect size of 0.2 was used. For all experiments biological replication of effect was obtained by the use of slices from at least three different litters of mice. Experiments that are depicted in the same graph were performed in parallel and with hippocampal slices of littermate mice. Data sets were Log-transformed and normal distributions were obtained. All data were analyzed using two-tailed Student *t* tests to compare 2 conditions (unpaired, unless indicated paired t-test) or with ANOVAs with post-hoc Tukey comparisons for more than 2 conditions. Reported p-values are post hoc contrasts, unless overall ANOVA was not significant. Repeated-Measures ANOVAs were used to assess effects over time. *P* values below 0.05 were considered statistically significant. For source data, please see Renner et al Source_data.xlsx.
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\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for submitting your work entitled \"Synaptic Plasticity through activation of AMPA-receptor subunit GluA3\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous. Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

Summary:

The reviewers and editors all recognized the interesting core result regarding the increase in open probability of hippocampal AMPA receptors upon exposure to PKA. They also noted, however, a number of technical questions, internal inconsistencies, relatively small sample sizes with respect to the variance, and possible alternative interpretations. Because it would take substantial additional experiments to address these points and resolve all the associated questions, we cannot consider this work further. (Although some points in the reviews brought up new types of experiments and the relation of this study to previous work, these issues were not the basis for our decision.) The full reviews are included below.

Reviewer \#1:

The manuscript by Renner et al. tests whether increasing cAMP levels in pyramidal neurons reveals a role of GluA3 in synaptic transmission. Understanding the mechanisms by which second messengers like cAMP regulate the properties of AMPA receptors and fast synaptic transmission is critical. The authors by using a series of electrophysiological and imaging experiments argue that under basal conditions GluA3 channels have very little contribution in synaptic transmission due to their low conductance and probability opening. However, when cAMP levels are elevated GluA3 shifts to a high-conductance state allowing them to contribute to point-to-point transmission in hippocampus. Importantly, this shift in the GluA3 mode is not due to PKA or EPAC, two well-established effectors of cAMP, but rather through Ras activation.

Although the authors\' findings provide a new insight in regards to the regulation of AMPA receptors in hippocampus, there are concerns with this work.

1\) Throughout, the authors use FSK or direct application of high levels of cAMP to test whether cAMP can increase the activity of AMPA receptors and in this work GluA3. It would have been important to also test whether the same effect occurs when cAMP is elevated through β-adrenergic receptors, a more physiologically relevant means to increase cAMP levels in hippocampus. In general it\'s unclear whether the effects are a result of a very large cAMP stimulus.

2\) They then argue that cAMP exerts its effects through Ras. Considering that, they also show that cAMP can induce its effects in outside-out patches, -- is Ras associated with GluA3? How do the authors know whether Ras directly activates GluA3 channels rather than regulate the relationship between TARPs or cornichons and GluA3; auxiliary AMPA receptor subunits known to control the biophysical properties of AMPA receptors? These questions should have been addressed in order to provide a mechanistic insight on how cAMP-Ras control AMPA receptors. Importantly, it would have been important to test the proposed cAMP and Ras mechanism in an expression system that does not natively express AMPA receptors, like HEK293 cells.

3\) The authors argue that application of FSK in slices increased the AMPA and NMDA ratio presumably due to potentiation of postsynaptic GluA3 receptors, as GluA3 null neurons do not show this increase in the AMPA/NMDA ratio. They argue against any presynaptic effects of FSK, as PPR did not change in the presence of FSK ([Figure 3](#fig3){ref-type="fig"}). However, they then show that FSK increases mEPSC frequency in the GluA3 null neurons, although not to the same extent as in control neurons. This would then suggest that FSK has presynaptic effects, which are not controlled in this work. Additionally, previous work has also shown that cAMP changes NMDA receptor activity (Raman et al. 1996; Westphal et al. 1999), as such the AMPA/NMDA ratio is difficult to quantitatively interpret in the presence and absence of FSK/cAMP.

Reviewer \#2:

In this manuscript Renner et al. reported that cAMP/FSK enhances GluA3-containing AMPAR-mediated currents in hippocampal neurons, similar to their finding in cerebellar Purkinje cells published earlier this year in Neuron (Gutierrez-Castellanos et al., 2017). Using outside-out patches and single channel recording of somatic membrane of CA1 neurons derived from WT, GluA1 or GluA3 KOs, they concluded that this enhancement is due to an increase in open probability of GluA3-containing AMPARs. Similar enhancements were observed at the synaptic level when analyzing AMPAR-mediated mEPSCs. The authors further explored signaling pathways underlying cAMP/FSK enhanced synaptic currents pharmacologically using inhibitors. This manuscript identifies a novel regulation of GluA3-containing AMPARs. However, due to the complexity of the effects of cAMP and some internal discrepancies in the data it is difficult to come to the simple conclusions presented by the authors. Specific comments are listed as the following:

1\) Assuming AMPARs in hippocampus are predominately in forms of GluA1/2 and GluA2/3, the authors compared cAMP/FSK-induced currents in WT (which contains both GluA1/2 and GluA2/3), GluA1 KO (which contains GluA2/3 only) and GluA3 KO (which contains GluA1/2 only). Since the GluA3 KO cells did not respond to cAMP/FSK like the WT and GluA1 KO did, the authors concluded that cAMP/FSK selectively potentiate currents from GluA\"2/3\" type of AMPARs. The Effect of cAMP could actually be on GluA2 when combined with GluA3. The title of this manuscript \"Synaptic Plasticity through activation of AMPA-receptor subunit GluA3\" is therefore somewhat misleading, as they did not show a direct effect of cAMP/FSK on GluA3 subunit nor provide its role in synaptic plasticity. Further evidence is required to make GluA3-specific claims and its effects on synaptic plasticity.

2\) The trafficking experiments done by live imaging of SEP-GluA3 delivered by sindbis virus ([Figure 1E](#fig1){ref-type="fig"}), as well as transfected SEP-GluA1 or SEP-GluA3 in CA1 neurons ([Figure 4](#fig4){ref-type="fig"}) are not convincing as these subunits when overexpressed alone tend to form homomers (GluA1/1 or GluA3/3) and may not reflect trafficking events of endogenous AMPARs (Sin et al., 2001). GluA3/3 in particular were reported to be absent in synapses even though it can be observed in spines. Alternative methodology examining endogenous AMPAR subunits such as isolation of PSD fraction of AMPARs or immunostaining of synaptic AMPARs would be a better approach.

3\) AMPA/NMDA ratio results are confusing. In [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, the major effect of FSK in WT cells appears to decrease NMDAR current, but leave AMPAR current unchanged. If so, what is the explanation? Is loss of the FSK effect on A/N ratio in GluA3 KO NMDAR-related?

4\) The rescue experiment, in which GFP-GluA3 is reintroduced into GluA3 KO to evaluate GluA3-specific manipulation in synaptic transmission, is not convincing. While the FSK-induced frequency increase in WT cells is \~4 fold (1 to 4 Hz), the magnitude in GluA3 KO is \~2 fold (1 to 2Hz, [Figure 1C](#fig1){ref-type="fig"}) similar to the magnitude obtained from the rescue condition (\~ 2 fold, 0.75 to 1.5 Hz, [Figure 1E](#fig1){ref-type="fig"}, GFP-GluA3 infected). The author should plot [Figure 3C and E](#fig3){ref-type="fig"} using the same scale for the ease of comparison of the frequency graphs. Similarly, the absence of FSK-induced potentiation in amplitude in GluA3 KO cells ([Figure 1C](#fig1){ref-type="fig"}, GluA3 KO) was not rescued in GFP-GluA3 infected GluA3 KO neurons ([Figure 1E](#fig1){ref-type="fig"}, GFP-GluA3 infected).

5\) FSK is well known to potentiate GluA1-containing AMPARs and FSK induced mEPSC frequency can be observed in WT, GluA3 KO and GluA1 KO neurons ([Figure 3C and D](#fig3){ref-type="fig"}), the pharmacology and antibody effects on mEPSC frequency done in WT cells (all experiments in [Figure 6](#fig6){ref-type="fig"}) are difficult to interpret. Further experiments using KO neurons are required to make a clear claim.

6\) In [Figure 6C](#fig6){ref-type="fig"}, the basal (FSK-/PKI+) mEPSC frequency in RAS-IgG neurons seems to be higher than the Ctrl-IgG. However, the basal (FSK-/PKI-) mEPSC frequency seems comparable between Ctrl-IgG and RAS-IgG neurons. If RAS-IgG neurons with PKI treatment do show a higher frequency than the Ctrl-IgG neurons, this would be an occlusion effect of PKI but not a blocking effect of RAS-IgG.

Reviewer \#3:

Renner et al. propose a novel mechanism of cAMP-mediated AMPA receptor current potentiation. By using AMPA receptor knockout mice, they dissect the contribution of the two AMPA subunits GluA1 and GluA3 to this effect. With recordings of extrasynaptic currents they show that cAMP alters conductance states of Glu3 but not of GluA1 channels. Recordings of synaptic currents and FRAP experiments suggest that this increase in GluA3 conductance rather than increased insertion of AMPA receptors into synapses is responsible for the cAMP-mediated synaptic potentiation. Finally, they describe that RAS activity is required for the cAMP-mediated synaptic potentiation.

The study is interesting as it identifies how \"dormant\" GluA3 channels are activated by cAMP. This finding, however, is not novel. The authors published this year another study on a very similar mechanism in Purkinje cells of the cerebellum (Gutierrez-Castellanos et al., Neuron 2017). There are some differences in the findings of the two studies (e.g. Epac vs. Ras dependency), but the main novelty of the current study is that cAMP influences GluA3 also in the hippocampus. Similar to the previous study, the authors provide high quality results of several experiments that very convincingly show the influence of cAMP on extrasynaptic GluA3 channels. However, results of extrasynaptic recordings are less convincing (see below). Finally, it would be important to show if and how much a cAMP-mediated increase in GluA3 currents contributes to a more physiological form of synaptic plasticity. In conclusion, the study is still preliminary in its present form and needs additional experiments for publication in *eLife*.

1\) Variability of mEPSC frequencies across experiments is very high. This precludes comparing results from the different experiments and drawing conclusions about the contribution of GluA1 or GluA3 from those comparisons. For example, mEPSC frequency in wildtype neurons without treatment differ by 0.7 Hz ([Figure 5E](#fig5){ref-type="fig"}: 0.7; [Figure 3F](#fig3){ref-type="fig"}: 1.4 Hz). In addition, the FSK-mediated increase is very different in wildtype neurons (+3.2 Hz in [Figure 3C](#fig3){ref-type="fig"} and 1.2 Hz in [Figure 5F](#fig5){ref-type="fig"}). In fact, the FSK-mediated increase shown in [Figure 5F](#fig5){ref-type="fig"} is similar to the increase in GluA3 knockout mice shown in [Figure 3C](#fig3){ref-type="fig"} (+ 1 Hz). Results shown in [Figure 3D](#fig3){ref-type="fig"} and [Figure 5D](#fig5){ref-type="fig"} strongly suggest that GluA3 channels play a role for the increase in synaptic strength in wildtype neurons. However, the contribution is most likely small ([Figure 3D](#fig3){ref-type="fig"} +0.6 Hz, [Figure 5D](#fig5){ref-type="fig"} +0.3 Hz). Again, the high variability of mEPSC frequency in the different experiments makes a direct comparison very difficult. Thus, my major concern is that experiments shown in [Figure 3](#fig3){ref-type="fig"}, [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"} do not allow drawing conclusions about the relevance of cAMP-mediated increase in GluA3 function for synaptic plasticity in CA1 neurons. That is for example in contrast to the study of Gutierrez-Castellanos et al. (Neuron 2017) that convincingly showed that GluA3 channels and the novel GluA3 plasticity play a role for synaptic function of Purkinje cells (mEPSC frequency, amplitude, LTP) and mouse behaviour (VOR).

2\) What was the rational to use acute brain slices from 3-5 weeks old mice in some experiments and organotypic slices of newborn mice in others? The mechanisms of FSK potentiation of synaptic currents might very well differ in the two preparations.

3\) The conclusion that Ras plays a role in GluA3-plasticity and competes with PKA-mediated GluA1-plasticity is not convincing. Except for the small increase in mEPSC amplitude, Ras-IgG have no influence on mEPSCs. In addition, experiments in [Figure 6C](#fig6){ref-type="fig"} are again very difficult to interpret since variability is high. Thus, is the lack of an effect of FSK explained because RAS-IgG increases mEPSC frequency in the -FSK control condition? mEPSC frequency in the presence of FSK is very similar irrespective of presence or absence of PKI or RAS-IgG ([Figure 6 B and C](#fig6){ref-type="fig"}). In addition, what was the rational to compare Fold-changes in frequency in [Figure 6 B-C](#fig6){ref-type="fig"} instead of mEPCS frequency as in all other experiments? Finally, the number of neurons analyzed should be increased. In fact, I am surprised that the small difference in Fold-change in 6C reaches significance with an N of 5 and I am pretty sure that there would be no significant difference in the FSK-mediated increase in mEPSC frequency between IgG and RAS-IgG.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for resubmitting your work entitled \"Synaptic Plasticity through activation of GluA3-containing AMPA-receptors\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Gary Westbrook (Senior Editor), a Reviewing Editor, and two reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

Remaining revisions:

Both reviewers acknowledged the value of the additional experiments but both brought up areas in which the interpretation of experiments should be constrained or clarified. Specifically,

1\) The experiments directly activating β-adrenergic receptors are interesting but the experiments were done under extreme (with IBMX) or nonspecific (with i.p.) conditions. The reviewers recognize that these are useful as proof of principle, but we suggest that the limitations of the experiment be made clear, particularly in discussions of the literature (e.g. extent to which these results can reconcile other studies).

2\) Also, the analysis of mEPSCs raised questions regarding the specificity/magnitude of the GluA3 contribution to the effect of blocking RAS/PKA. Please interpret/explain the data in context of the difference in baseline rates between wild-type and KO, and curtail and/or clarify the conclusions accordingly.

The full comments of the reviewers are given below to place the comments in context. We expect that these points can be addressed with textual/figure revisions.

Reviewer \#1:

This is a revised manuscript by Renner et al. showing that high concentrations of cAMP facilitates AMPA receptors through GluA3 subunits. The authors have performed several new experiments that clarify and support their previous conclusions. However, one of my previous concerns was the use of very high concentrations of cAMP or the use of FSK. To address this they tested whether activation of β-adrenergic receptors -- a more physiologically relevant experiment -- can also lead to GluA3 mediated plasticity. They indeed demonstrate that application of ISO evokes GluA3 potentiation, however only when PDEs are blocked. This suggests that the proposed GluA3 plasticity might take place under non-physiological conditions. They also show that i.p. injection of EPI in mice could lead to GluA3 AMPA receptor potentiation. This experiment is very difficult to interpret, as global activation of b-adrenergic receptors will initiate multiple downstream signaling pathways. Due to these reasons my enthusiasm for this work is still dampened.

Reviewer \#3:

Renner and colleagues added a substantial number of new experiments that clarified some concerns. In particular the experiments shown in [Figure 7](#fig7){ref-type="fig"} increased the novelty of the study and provided evidence that physiological stimuli can induce cAMP-mediated activation of GluA3-containing AMPA-receptors. In conclusion, the comprehensive study of Renner et al. is largely convincing and suitable for publication in *eLife*.

I am still not convinced by the mEPSC data as the high variability of mEPSC frequency within one genotype precludes drawing conclusions about the contribution of GluA3 during cAMP mediated changes in synaptic function. A calculation of fold-change in frequency is not really helpful for an estimation of the contribution of GluA3. Absolute changes in frequency have to be compared for such an estimation. The very small increase in mEPSC frequency in GluA1 KO mice (approx. 0.1 Hz in [figure 6](#fig6){ref-type="fig"}) compared to the much bigger increase in wt mice (approx. 0.5 Hz also in [Figure 6](#fig6){ref-type="fig"}) suggests that the contribution of GluA2/3 heteromers is rather small. Please discuss.

10.7554/eLife.25462.023

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

Reviewer \#1:

\[...\] Although the authors\' findings provide a new insight in regards to the regulation of AMPA receptors in hippocampus, there are concerns with this work.

1\) Throughout, the authors use FSK or direct application of high levels of cAMP to test whether cAMP can increase the activity of AMPA receptors and in this work GluA3. It would have been important to also test whether the same effect occurs when cAMP is elevated through β-adrenergic receptors, a more physiologically relevant means to increase cAMP levels in hippocampus. In general it\'s unclear whether the effects are a result of a very large cAMP stimulus.

In the revised manuscript we have added a new experiment that indicates that the activation of β-adrenergic receptors by isoproterenol triggers GluA3-dependent synaptic potentiation in CA1 neurons in brain slices ([Figure 7](#fig7){ref-type="fig"}). In addition, we show that NE-release in the hippocampus induced by i.p. epinephrine injection leads to GluA3-dependent synaptic potentiation in CA1 neurons ([Figure 8](#fig8){ref-type="fig"}).

2\) They then argue that cAMP exerts its effects through Ras. Considering that, they also show that cAMP can induce its effects in outside-out patches, -- is Ras associated with GluA3? How do the authors know whether Ras directly activates GluA3 channels rather than regulate the relationship between TARPs or cornichons and GluA3; auxiliary AMPA receptor subunits known to control the biophysical properties of AMPA receptors? These questions should have been addressed in order to provide a mechanistic insight on how cAMP-Ras control AMPA receptors. Importantly, it would have been important to test the proposed cAMP and Ras mechanism in an expression system that does not natively express AMPA receptors, like HEK293 cells.

When obtaining outside-out patches, cAMP is present in the recording pipette and allowed to diffuse into the cell body upon achieving whole-cell configuration for up to \~10 seconds. Within this time frame, outside-out patches were pulled, which showed increased AMPAR currents. Thus, within seconds cAMP triggered intracellular signaling leading to increased AMPAR currents. When we repeated this experiment without adding cAMP in the recording pipette, but instead we pulled inside-out patches and used direct application of cAMP onto these inside-out patches, we did not observe an activation of GluA3-dependent plasticity ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). This experiment argues against cAMP directly activating proteins associated with the AMPAR complex.

We have expanded our experiments on the dependency of Ras of the activation of GluA3-plasticity ([Figure 6](#fig6){ref-type="fig"} in revised manuscript). These experiments reveal that both Ras and PKA activation need to be blocked to prevent synaptic potentiation of GluA3-containing AMPARs. We discuss the implications of these findings in the second paragraph of the Discussion section.

The PKA/Ras signaling pathway has been described previously in non-neuronal cells. Our study is the first to show a functional consequence of PKA/Ras signaling in neurons. How PKA/Ras signaling leads to the activation of GluA2/3 channels we will address during the next years in collaboration with experts on PKA/Ras signaling and with experts on AMPAR structure/function relationships.

3\) The authors argue that application of FSK in slices increased the AMPA and NMDA ratio presumably due to potentiation of postsynaptic GluA3 receptors, as GluA3 null neurons do not show this increase in the AMPA/NMDA ratio. They argue against any presynaptic effects of FSK, as PPR did not change in the presence of FSK ([Figure 3](#fig3){ref-type="fig"}). However, they then show that FSK increases mEPSC frequency in the GluA3 null neurons, although not to the same extent as in control neurons. This would then suggest that FSK has presynaptic effects, which are not controlled in this work. Additionally, previous work has also shown that cAMP changes NMDA receptor activity (Raman et al. 1996; Westphal et al. 1999), as such the AMPA/NMDA ratio is difficult to quantitatively interpret in the presence and absence of FSK/cAMP.

The main conclusion of our manuscript is that a rise in cAMP increases postsynaptic GluA3-dependent currents. That a rise in cAMP besides postsynaptic changes, also produces presynaptic plasticity, is not challenged by us. Nevertheless, in our experimental preparations forskolin predominantly produced postsynaptic effects in CA1 neurons, which is in line with a previous study (Sokolova et al., 2006). This conclusion is based on the following observations/analyses:

\- Forskolin produced an increase in AMPA/NMDA ratio in WT neurons, but not in GluA3-KO neurons. A variance analysis on our recordings of AMPA/NMDA ratios in WT neurons ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) indicates that:

a\) forskolin did not detectably increase the presynaptic release probability;

b\) forskolin increased AMPAR currents without a change in NMDAR currents.

This analysis indicates that the effects of forskolin on synapses in our experiments were in large part postsynaptic in nature. The detailed explanation of these conclusions based on the variance analysis is provided in the legend of [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}.

\- A change in mEPSC frequency does not necessarily reflect a change in presynaptic plasticity, but can also reflect a postsynaptic change in AMPAR currents as shown in previous studies (e.g.: Watson et al., 2017; Lee et al., 2014; Lu et al., 2009; Rumbaugh et al., 2006). We plotted the distribution of mEPSC amplitudes recorded from GluA1-KO neurons ([Figure 3G](#fig3){ref-type="fig"}), and this suggests that a substantial proportion of mEPSC events fell below the 5 pA detection limit. In the presence of forskolin the proportion that reached above detection limit appeared to become larger (i.e. a rightward shift in [Figure 3G](#fig3){ref-type="fig"}). A further explanation of this notion is provided in the fourth paragraph of the Discussion section.

\- We added a non-stationary noise analysis of scaled mESPCs in [Figure 3E and 3F](#fig3){ref-type="fig"} of the revised manuscript. This analysis demonstrates that forskolin triggered an increase in postsynaptic single-channel conductance at synapses only when neurons express GluA3.

Reviewer \#2: \[...\] 1) Assuming AMPARs in hippocampus are predominately in forms of GluA1/2 and GluA2/3, the authors compared cAMP/FSK-induced currents in WT (which contains both GluA1/2 and GluA2/3), GluA1 KO (which contains GluA2/3 only) and GluA3 KO (which contains GluA1/2 only). Since the GluA3 KO cells did not respond to cAMP/FSK like the WT and GluA1 KO did, the authors concluded that cAMP/FSK selectively potentiate currents from GluA\"2/3\" type of AMPARs. The Effect of cAMP could actually be on GluA2 when combined with GluA3. The title of this manuscript \"Synaptic Plasticity through activation of AMPA-receptor subunit GluA3\" is therefore somewhat misleading, as they did not show a direct effect of cAMP/FSK on GluA3 subunit nor provide its role in synaptic plasticity. Further evidence is required to make GluA3-specific claims and its effects on synaptic plasticity.

To address this issue, we expressed GFP-GluA2Q in GluA3-deficient neurons. GluA2Q forms predominantly GluA2/2 homomers and constitutively traffics into synapses, similar to GluA2/3s (Shi et al., 2001; Makino and Malinow, 2011). Notably, GluA2Q-expressing neurons reacted similarly to forskolin compared with GluA3-expressing ones: both showed an increased mEPSC frequency upon forskolin application to a similar extent (see [Author response image 1](#respfig1){ref-type="fig"}).

These data suggest that the cAMP-driven increase in AMPAR-channel conductance is not an exclusive feature of GluA3, but may also be held by GluA2. This is perhaps not surprising, considering that GluA2 and GluA3 are quite homologous in amino acid composition and structure. GluA1/2 heteromers do not show an increase in channel conductance upon a rise in cAMP, implying that GluA1 may suppress the ability of GluA2 to increase currents when cAMP levels rise. However, this needs further investigation. Because we feel this further investigation falls beyond the scope of this manuscript, we decided to not include this experiment in the current manuscript. However, if the reviewers prefer, we are happy to include this figure in the revised manuscript.

Based on this experiment, we have adapted our wording throughout the manuscript. We have changed the title into: "Synaptic Plasticity through Activation of GluA3-containing AMPA-receptors". In addition, through the revised manuscript we use the terminology of either 'GluA3-dependent plasticity' or 'GluA2/3-plasticity', instead of 'GluA3-plasticity'.

![mEPSC frequency and amplitude of GluA3-deficient neurons, infected with GFP-GluA3 (blue) or GFP-GluA2Q (yellow) in the absence (even) or presence (blocked bar) of forskolin.](elife-25462-resp-fig1){#respfig1}

2\) The trafficking experiments done by live imaging of SEP-GluA3 delivered by sindbis virus ([Figure 1E](#fig1){ref-type="fig"}), as well as transfected SEP-GluA1 or SEP-GluA3 in CA1 neurons ([Figure 4](#fig4){ref-type="fig"}) are not convincing as these subunits when overexpressed alone tend to form homomers (GluA1/1 or GluA3/3) and may not reflect trafficking events of endogenous AMPARs (Sin et al., 2001). GluA3/3 in particular were reported to be absent in synapses even though it can be observed in spines. Alternative methodology examining endogenous AMPAR subunits such as isolation of PSD fraction of AMPARs or immunostaining of synaptic AMPARs would be a better approach.

We agree that it would be preferable if we could complement our data with alternative methodology like immunohistochemistry. In collaboration with the lab of Prof. Guus Smit, we have tested a set of commercially available GluA3 antibodies in immunohistochemistry and immunoprecipitation experiments. Unfortunately, all of these antibodies showed substantial staining in GluA3-KO samples and showed cross-reactivity in immunoprecipitation experiments.

To assess whether the overexpression of GluA3 leads to the formation of GluA3/3 homomers, we expressed GFP-GluA3 in GluA3-KO neurons through sindbis infection and measured the rectification index of AMPAR currents in the presence of FSK. The AMPAR currents were in fact significantly *less* rectifying compared with uninfected GluA3-deficent neurons in the same slices. This experiment indicates that overexpressed GFP-GluA3 predominantly reached synapses in the configuration of GluA2/3 heteromers. This new experiment is added to the revised manuscript in [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}.

With respect to SEP-GluA1 overexpression: in an imaging experiment similar to our experiment in [Figure 4](#fig4){ref-type="fig"}, it was previously shown that GluA1/1 homomers behave similarly as GluA1/2 heteromers with respect to synaptic trafficking (Makino and Malinow, 2011).

Importantly, our results obtained with AMPAR subunit overexpression match and complement our results from AMPAR subunit knockout models.

3\) AMPA/NMDA ratio results are confusing. In [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, the major effect of FSK in WT cells appears to decrease NMDAR current, but leave AMPAR current unchanged. If so, what is the explanation? Is loss of the FSK effect on A/N ratio in GluA3 KO NMDAR-related?

We apologize for the poor explanation of the variance analysis in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. This experiment in fact demonstrates that FSK did not change NMDAR currents.

In this experiment we stimulated WT neurons to achieve AMPAR responses of approximately 50 pA. At this stimulation strength, NMDAR currents were subsequently measured. These were significantly smaller in the FSK condition, resulting in an increased AMPA/NMDA ratio. This can be the result of 1) increased AMPAR currents or 2) decreased NMDAR currents. To assess whether the increased AMPA/NMDA ratio is a consequence of increased AMPAR currents or decreased NMDAR currents, we performed a variance analysis to determine the quantal content (QC) of glutamate release. The QC can be calculated based on the coefficient of variation (CV) and depends on both presynaptic release probability (Pr) and on the number of active synapses (N) that are stimulated, but not on postsynaptic quantal size (q), as shown in the following equation:

1/CV^[@bib2]^ = N x Pr/(1-Pr)

In the presence of FSK, a significantly lower QC is sufficient to achieve 50 pA AMPAR responses. However, the NMDAR responses are lower proportional to a lower QC in the presence of FSK (see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

Interpretation of these results:

A lower QC can mean either a lower Pr, or a lower N. Irrespectively, these data indicate that forskolin increased postsynaptic AMPAR strength, since AMPAR amplitude of 50 pA were achieved despite a lower P~r~ or N.

It is unlikely that FSK substantially *lowered* presynaptic release probability, since we show that forskolin led to synaptic potentiation expressed by increased mEPSC frequency and amplitude ([Figure 3C](#fig3){ref-type="fig"}).

Thus, the change in QC is most likely reflects a change in 'N'. Specifically, fewer synapses (approximately two-fold lower N) were stimulated to reach 50 pA AMPAR responses. When stimulating these \~2-fold fewer synapses, \~2-fold lower NMDAR currents were measured.

Based on this analysis we propose that FSK led to an on average \~2-fold increase in postsynaptic AMPAR currents, without a significant change in NMDAR currents and without an increase in presynaptic release probability.

4\) The rescue experiment, in which GFP-GluA3 is reintroduced into GluA3 KO to evaluate GluA3-specific manipulation in synaptic transmission, is not convincing. While the FSK-induced frequency increase in WT cells is \~4 fold (1 to 4 Hz), the magnitude in GluA3 KO is \~2 fold (1 to 2Hz, [Figure 1C](#fig1){ref-type="fig"}) similar to the magnitude obtained from the rescue condition (\~ 2 fold, 0.75 to 1.5 Hz, [Figure 1E](#fig1){ref-type="fig"}, GFP-GluA3 infected). The author should plot [Figure 3C and E](#fig3){ref-type="fig"} using the same scale for the ease of comparison of the frequency graphs. Similarly, the absence of FSK-induced potentiation in amplitude in GluA3 KO cells ([Figure 1C](#fig1){ref-type="fig"}, GluA3 KO) was not rescued in GFP-GluA3 infected GluA3 KO neurons ([Figure 1E](#fig1){ref-type="fig"}, GFP-GluA3 infected).

We generally observe variations in average basal transmission of CA1 neurons between slices from different animals. In order to make comparisons across different experiments, we therefore normalize the experimental effects to their matched control conditions.

In the revised manuscript we only use data in which the experimental condition (e.g. cAMP application, forskolin, isoproterenol) has been performed in the same sets of slices as the control condition recorded on the same day, and in each experiment we use slices from multiple animals. In the original [Figure 3](#fig3){ref-type="fig"}, the WT and GluA3-KO inadvertently contained mEPSC recordings in which the ctrl and forskolin condition were obtained from different animals. We have corrected this in the revised manuscript. Due to the variation in basal transmission we assess the ability of cAMP to increase in synaptic transmission in different genotypes by comparing the fold change of the forskolin condition compared to control condition.

In the rescue experiment, the effect of GFP-GluA3 expression was tested as soon as 24 hrs after viral infection, and at this time point the forskolin-driven fold increase in mEPSC frequency was already partially rescued. The rescue experiment is particularly well-controlled since all conditions (GluA3-KO with and without GFP-GluA3 and with and without forskolin) were recorded on the same day on the same preparations of slices.

5\) FSK is well known to potentiate GluA1-containing AMPARs and FSK induced mEPSC frequency can be observed in WT, GluA3 KO and GluA1 KO neurons ([Figure 3C and D](#fig3){ref-type="fig"}), the pharmacology and antibody effects on mEPSC frequency done in WT cells (all experiments in [Figure 6](#fig6){ref-type="fig"}) are difficult to interpret. Further experiments using KO neurons are required to make a clear claim.

We have expanded the experiments with antiRas-IgG infusion in WT neurons and have repeated these experiments in GluA1-KO neurons, as shown in [Figure 6](#fig6){ref-type="fig"} of the revised manuscript. These new experiments now show that the forskolin-driven potentiation of GluA2/3 currents depends on the activation of both Ras and PKA. The blockade effect of Ras and PKA was indeed most pronounced when GluA2/3 currents are isolated in GluA1-KO slices.

*6) In [Figure 6C](#fig6){ref-type="fig"}, the basal (FSK-/PKI+) mEPSC frequency in RAS-IgG neurons seems to be higher than the Ctrl-IgG. However, the basal (FSK-/PKI-) mEPSC frequency seems comparable between Ctrl-IgG and RAS-IgG neurons. If RAS-IgG neurons with PKI treatment do show a higher frequency than the Ctrl-IgG neurons, this would be an occlusion effect of PKI but not a blocking effect of RAS-IgG.*

We have analyzed the effects of infusion of antiRas-IgG and ctrl-IgG and of PKI on basal transmission in both WT and GluA1-KO CA1 neurons, and this analysis shows that they do not significantly affect synaptic currents, as shown in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} of the revised manuscript.

Reviewer \#3: \[...\] 1) Variability of mEPSC frequencies across experiments is very high. This precludes comparing results from the different experiments and drawing conclusions about the contribution of GluA1 or GluA3 from those comparisons. For example, mEPSC frequency in wildtype neurons without treatment differ by 0.7 Hz ([Figure 5E](#fig5){ref-type="fig"}: 0.7; [Figure 3F](#fig3){ref-type="fig"}: 1.4 Hz). In addition, the FSK-mediated increase is very different in wildtype neurons (+3.2 Hz in [Figure 3C](#fig3){ref-type="fig"} and 1.2 Hz in [Figure 5F](#fig5){ref-type="fig"}). In fact, the FSK-mediated increase shown in [Figure 5F](#fig5){ref-type="fig"} is similar to the increase in GluA3 knockout mice shown in [Figure 3C](#fig3){ref-type="fig"} (+ 1 Hz). Results shown in [Figure 3D](#fig3){ref-type="fig"} and [Figure 5D](#fig5){ref-type="fig"} strongly suggest that GluA3 channels play a role for the increase in synaptic strength in wildtype neurons. However, the contribution is most likely small ([Figure 3D](#fig3){ref-type="fig"} +0.6 Hz, [Figure 5D](#fig5){ref-type="fig"} +0.3 Hz). Again, the high variability of mEPSC frequency in the different experiments makes a direct comparison very difficult. Thus, my major concern is that experiments shown in [Figure 3](#fig3){ref-type="fig"}, [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"} do not allow drawing conclusions about the relevance of cAMP-mediated increase in GluA3 function for synaptic plasticity in CA1 neurons. That is for example in contrast to the study of Gutierrez-Castellanos et al. (Neuron 2017) that convincingly showed that GluA3 channels and the novel GluA3 plasticity play a role for synaptic function of Purkinje cells (mEPSC frequency, amplitude, LTP) and mouse behaviour (VOR).

We observed that the variability between experiments is a consequence of differences in basal synaptic transmission between animals. In the revised [Figure 3](#fig3){ref-type="fig"}, we only compare control and forskolin condition between neurons of slices of the same age and obtained from the same animal. To allow us to compare between experiments, we calculate the 'fold change' (forskolin relative to control). These experiments demonstrate that the forskolin-mediated synaptic potentiation is in large part dependent on the presence of AMPAR subunit GluA3.

In the revised manuscript we added a new set of experiments ([Figure 7](#fig7){ref-type="fig"}) showing that β-adrenergic signaling in the hippocampus induces GluA3-dependent synaptic potentiation in CA1 neurons, thereby providing a more physiological form of this type of plasticity.

In all experiments throughout the revised manuscript we consistently show that GluA3 significantly contributes to the cAMP-mediated AMPAR potentiation. In [Figures 3](#fig3){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and in the newly added [Figures 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"} we show that a rise in cAMP (either through application of cAMP, FSK or β-ADR activation) in all cases significantly potentiates synaptic currents in a GluA3-dependent fashion. In addition, we added a new experiment in which we show that selectively knocking-out GluA3 in CA1 neurons in a conditional GluA3-KO model prevents synaptic potentiation upon NE-release in the hippocampus ([Figure 8C](#fig8){ref-type="fig"}), indicating that the absence of a cAMP-mediated synaptic potentiation is not a consequence of aberrant neuronal developmental.

2\) What was the rational to use acute brain slices from 3-5 weeks old mice in some experiments and organotypic slices of newborn mice in others? The mechanisms of FSK potentiation of synaptic currents might very well differ in the two preparations.

The rational for using acute brain slices in [Figure 6](#fig6){ref-type="fig"} is that these experiments require whole cell recordings to be stable for up to 30 minutes, which in our hands are somewhat more efficient when performed in acute slices compared with organotypic slices.

We note that our findings in acute brain slices closely match those in organotypic slices. For instance, the application of β-ADR agonist isoproterenol gave a similar level of synaptic potentiation in acute versus organotypic slices (see [Author response image 2](#respfig2){ref-type="fig"}).

![Incubation of wild-type CA1 neurons with isoproterenol and IBMX increased the mEPSC frequency, but not amplitude.](elife-25462-resp-fig2){#respfig2}

3\) The conclusion that Ras plays a role in GluA3-plasticity and competes with PKA-mediated GluA1-plasticity is not convincing. Except for the small increase in mEPSC amplitude, Ras-IgG have no influence on mEPSCs. In addition, experiments in [Figure 6C](#fig6){ref-type="fig"} are again very difficult to interpret since variability is high. Thus, is the lack of an effect of FSK explained because RAS-IgG increases mEPSC frequency in the -FSK control condition? mEPSC frequency in the presence of FSK is very similar irrespective of presence or absence of PKI or RAS-IgG ([Figure 6 B and C](#fig6){ref-type="fig"}). In addition, what was the rational to compare Fold-changes in frequency in [Figure 6 B-C](#fig6){ref-type="fig"} instead of mEPCS frequency as in all other experiments? Finally, the number of neurons analyzed should be increased. In fact, I am surprised that the small difference in Fold-change in 6C reaches significance with an N of 5 and I am pretty sure that there would be no significant difference in the FSK-mediated increase in mEPSC frequency between IgG and RAS-IgG.

We have increased the N in our recordings from WT CA1 neurons, and we have repeated this experiment in GluA1-KO neurons to isolate the effect of Ras and PKA blockade on GluA2/3 currents. These new experiments revealed that the forskolin-driven increase in mEPSC frequency is significantly prevented when both Ras and PKA were blocked.

\[Editors' note: the author responses to the re-review follow.\]

Reviewer \#1:

This is a revised manuscript by Renner et al. showing that high concentrations of cAMP facilitates AMPA receptors through GluA3 subunits. The authors have performed several new experiments that clarify and support their previous conclusions. However, one of my previous concerns was the use of very high concentrations of cAMP or the use of FSK. To address this they tested whether activation of β-adrenergic receptors -- a more physiologically relevant experiment -- can also lead to GluA3 mediated plasticity. They indeed demonstrate that application of ISO evokes GluA3 potentiation, however only when PDEs are blocked. This suggests that the proposed GluA3 plasticity might take place under non-physiological conditions. They also show that i.p. injection of EPI in mice could lead to GluA3 AMPA receptor potentiation. This experiment is very difficult to interpret, as global activation of b-adrenergic receptors will initiate multiple downstream signaling pathways. Due to these reasons my enthusiasm for this work is still dampened.

We agree with the reviewer that GluA2/3-plasticity requires a robust increase in cAMP. Our finding that isoproterenol (ISO) by itself failed to induce GluA2/3-plasticity is actually not that surprising, considering that ISO is known generate a very weak rise in intracellular cAMP \[Chay et al., 2016; Bruss et al., 2008\]. This is because β-AR activation, besides adenylyl cyclase, also triggers the activation of PDEs, leading to a negative feedback loop, which significantly inhibits cAMP downstream signaling \[Houslay and Baillie, 2005; Bruss et al., 2008\]. This explains why we could only observe GluA2/3plasticity upon exposure of CA1 neurons to ISO when PDEs were inhibited.

The idea is that a robust increase in cAMP is only achieved when β-AR activation coincides with a rise in Ca^2+^ (e.g. upon NMDAR activation), which catalyzes cAMP production \[Chetkovich and Sweatt, 1993; Wayman et al., 1994; Chay et al., 2016\]. A short description of these considerations, including references, are added to the Results subsection "β-adrenergic signaling triggers the activation of GluA2/3-plasticity".

We regret that this reviewer cannot bolster more enthusiasm for our experiments in which we show that β-AR activation in vivo upon Epi-injection is sufficient to trigger GluA2/3-plasticity. These data indicate that GluA2/3plasticity is active under physiological conditions.

*Reviewer \#3:*

\[...\] I am still not convinced by the mEPSC data as the high variability of mEPSC frequency within one genotype precludes drawing conclusions about the contribution of GluA3 during cAMP mediated changes in synaptic function. A calculation of fold-change in frequency is not really helpful for an estimation of the contribution of GluA3. Absolute changes in frequency have to be compared for such an estimation. The very small increase in mEPSC frequency in GluA1 KO mice (approx. 0.1 Hz in [figure 6](#fig6){ref-type="fig"}) compared to the much bigger increase in wt mice (approx. 0.5 Hz also in [Figure 6](#fig6){ref-type="fig"}) suggests that the contribution of GluA2/3 heteromers is rather small. Please discuss.

In our experiments an increase in mEPSC frequency is predominantly the result of the sizes of mEPSCs rising above the 5 pA detection limit. An increase in mEPSC frequency cannot be directly quantified into the absolute level of the change in postsynaptic strength. It can be compared between conditions as a relative change in synapse strength, provided that both conditions show a similar distribution of mEPSC events around the 5 pA detection limit.

However, the average mEPSC amplitude and frequency are substantially lower in GluA1-KO neurons compared with WT ones, and when we plot the distribution of mEPSC events recorded from WT and GluA1-KO neurons as shown in [Figure 6](#fig6){ref-type="fig"}, the distribution of mEPSC events before FSK/IBMX application is clearly different in GluA1-KO versus WT neurons (see [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Thus, the absolute increase in mEPSC frequency cannot be directly compared between WT and GluA1-KO neurons.

Due to the absence of GluA1, GluA1-KO neurons have experienced little activity-dependent AMPAR plasticity, and as a consequence the synapses have not matured as much as WT neurons and synapses contain on average lower amounts of AMPARs. In WT neurons GluA1-containing AMPARs at synapses are gradually replaced by GluA2/3s. For this reason, it is conceivable that WT neurons have more GluA2/3s at synapses compared with GluA1-KO neurons. This notion may well explain why the absolute change in mEPSC frequency upon the activation of GluA2/3-plasticity is larger in WT neurons compared with GluA1-KO neurons.

In conclusion, the larger increase in mEPSC frequency in WT neurons compared with GluA1-KO neurons does [not]{.ul} reflect a small contribution of GluA2/3 plasticity to the cAMP-driven synaptic potentiation.

Results in experiments in [Figure 1A](#fig1){ref-type="fig"} and [Figure 3A](#fig3){ref-type="fig"} can be directly quantified, and these indicate that a rise in cAMP driven by FSK lead to a two-fold increase in both extrasynaptic ([Figure 1A](#fig1){ref-type="fig"}) and synaptic ([Figure 3A](#fig3){ref-type="fig"}) AMPAR currents. Importantly, FSK does not increase AMPAR currents in GluA3-KO neurons, indicating that the cAMP-driven increase in synaptic currents is predominantly a consequence of GluA2/3-plasticity.

To clarify this issue, we have included the distributions of mEPSC events as [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"} in the revised manuscript.

[^1]: These authors contributed equally to this work.
